[Tuberculosis and HIV infection: experience of the national tuberculosis prevention program in Djibouti: 1990-1996].
Based on analysis of data collected from the national tuberculosis prevention program in Djibouti between 1990 and 1996, the authors analyzed the relationship between HIV infection and tuberculosis. The study cohort comprised a total of 22,000 patients including 14,000 with documented HIV infection. Although HIV infection probably worsened the situation, it was neither the only nor the main factor involved in the resurgence of tuberculosis. Demographic growth, higher population density, and increasing poverty as well as the quality of the national tuberculosis prevention program must be taken into account. The incidence of smear-negative tuberculosis was not significantly higher in HIV-infected patients (incidence of smear positive cases, > 92%). Extrapulmonary tuberculosis especially of pleural involvement was more common (15% versus 9.4%). Treatment was effective in HIV-infected patients. If directly observed (DOT) therapy was used, there was no risk of emergence of multidrug-resistant tuberculosis strains. Drug side-effects associated with the protocols used in Djibouti were not greater in HIV-infected patients. Most additional mortality observed in HIV-infected tuberculosis patients (10.5% versus 2%) was due to progression of HIV infection.
Renoux
E
E
Service de Pneumologie, Hôpital d'Instruction des Armées R. Picqué, 33998 Bordeaux, France. renouxe@club-internet.fr
Matan
A Barreh
AB
Sevre
J P
JP
Mohamed Ali
I
I
Chami
D
D
Vincent
V
V
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D015730:Djibouti / Q000453:epidemiology; D004352:Drug Resistance, Microbial; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D011156:Population Density; D011203:Poverty; D018088:Tuberculosis, Multidrug-Resistant / Q000150:complications / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*
D000995:Antitubercular Agents